CSF1R and breast cancer: Several clinical trials have evaluated the efficacy and safety of Pexidartinib and PLX3397 (targeting the CSF1/CSF-1R axis) in combination with Eribulin (NCT01596751) and Paclitaxel (NCT01525602) in patients with metastatic BC, but the results are difficult to assess due to the small patient sample.